STCube Inc (052020) - Total Liabilities

Latest as of June 2026: ₩18.51 Billion KRW ≈ $12.54 Million USD

Based on the latest financial reports, STCube Inc (052020) has total liabilities worth ₩18.51 Billion KRW (≈ $12.54 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 052020 long-term investment intensity to see how much of total assets are deployed in long-term investments.

STCube Inc - Total Liabilities Trend (2009–2025)

This chart illustrates how STCube Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 052020 total asset value.

STCube Inc Competitors by Total Liabilities

The table below lists competitors of STCube Inc ranked by their total liabilities.

Company Country Total Liabilities
Forrester Research Inc
NASDAQ:FORR
USA $303.01 Million
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
Turkey TL10.62 Billion
FENIX Resources Ltd
AU:FEX
Australia AU$186.70 Million
Varia US Properties Ltd
SW:VARN
Switzerland CHF656.47 Million
Joyce Corporation Ltd
AU:JYC
Australia AU$57.55 Million
Capral Ltd
AU:CAA
Australia AU$239.10 Million
Donpon Precision
TWO:3290
Taiwan NT$2.37 Billion
MEDIFAST INC
NYSE:MED
USA $64.02 Million

Liability Composition Analysis (2009–2025)

This chart breaks down STCube Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of STCube Inc to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 15.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.31 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how STCube Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for STCube Inc (2009–2025)

The table below shows the annual total liabilities of STCube Inc from 2009 to 2025.

Year Total Liabilities Change
2025-12-31 ₩18.11 Billion
≈ $12.27 Million
+2.74%
2024-12-31 ₩17.63 Billion
≈ $11.95 Million
+65.54%
2023-12-31 ₩10.65 Billion
≈ $7.22 Million
+8.11%
2022-12-31 ₩9.85 Billion
≈ $6.68 Million
+1.58%
2021-12-31 ₩9.70 Billion
≈ $6.57 Million
-32.79%
2020-12-31 ₩14.43 Billion
≈ $9.78 Million
-38.77%
2019-12-31 ₩23.56 Billion
≈ $15.97 Million
+18.32%
2018-12-31 ₩19.91 Billion
≈ $13.50 Million
+171.44%
2017-12-31 ₩7.34 Billion
≈ $4.97 Million
-36.40%
2016-12-31 ₩11.54 Billion
≈ $7.82 Million
+370.34%
2015-12-31 ₩2.45 Billion
≈ $1.66 Million
-74.73%
2014-12-31 ₩9.70 Billion
≈ $6.58 Million
-41.65%
2013-12-31 ₩16.63 Billion
≈ $11.27 Million
+237.74%
2012-12-31 ₩4.92 Billion
≈ $3.34 Million
-9.52%
2011-12-31 ₩5.44 Billion
≈ $3.69 Million
+35.83%
2010-12-31 ₩4.01 Billion
≈ $2.72 Million
+19.03%
2009-12-31 ₩3.37 Billion
≈ $2.28 Million
--

About STCube Inc

KQ:052020 Korea Electronic Equipment & Parts
Market Cap
$131.64 Million
₩194.24 Billion KRW
Market Cap Rank
#18233 Global
#805 in Korea
Share Price
₩7260.00
Change (1 day)
-0.95%
52-Week Range
₩6490.00 - ₩22100.00
All Time High
₩24627.95
About

STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more